ACM
XENE icon

Ativo Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Ativo Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-137,389
Closed -$2.32M – 248
2015
Q1 		$2.32M Buy
+137,389
New +$2.54M 0.91% 26

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
IPC
Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ativo Capital Management's XENE Position: Q2 2015 in Review

Ativo Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2015, closing a stake of 137,389 shares — an estimated $2.32M sold.

Ativo Capital Management first reported a position in XENE in Q1 2015 and held it in 1 quarter. The position peaked at $2.32M in Q1 2015. 26 funds tracked by Wall St. Rank hold XENE as of Q2 2015.

  • Ativo Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Ativo Capital Management sold 137,389 Xenon Pharmaceuticals shares in Q2 2015, an estimated $2.32M.
  • Ativo Capital Management first reported a position in Xenon Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Ativo Capital Management's Xenon Pharmaceuticals position peaked at $2.32M in Q1 2015.
  • 26 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2015.

Based on Ativo Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.